Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT07919457
PHASE2

Phenotype-based Model for Managing Chronic Post-treatment Pain Among Head and Neck Cancer Survivors: a Pilot Study

Sponsor: Shaukat Khanum Memorial Cancer Hospital & Research Centre

View on ClinicalTrials.gov

Summary

The goal of this clinical trial is to find out whether a phenotype-based pain management approach can reduce chronic pain in adults (18 years and older) who have completed curative treatment for head and neck cancer and continue to experience chronic post-treatment pain. The main questions it aims to answer are: * Does a phenotype-based pain management approach reduce participants' average pain by at least 75% after one month of treatment? * Is the treatment safe, with 10% or fewer participants stopping treatment because of side effects? Participants will: * Attend three study visits over one month (at baseline, 2 weeks, and 4 weeks). * Complete questionnaires about their pain, anxiety, depression, medication side effects, and use of pain medicines. * Undergo a detailed examination to identify the type (phenotype) of their pain. * Receive a treatment plan tailored to their pain phenotype, which may include medications, trigger point injections, or nerve blocks, depending on their symptoms and pain severity. * Return for follow-up visits to assess pain relief, medication side effects, and use of breakthrough pain medication.

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

40

Start Date

2026-07-16

Completion Date

2027-02-28

Last Updated

2026-11-05

Healthy Volunteers

No

Interventions

OTHER

Myofascial Pain

Participants with myofascial pain disorder will initially receive muscle relaxants, such as tizanidine (up to 8 mg per day), cyclobenzaprine (up to 30 mg per day), or amitriptyline (up to 25 mg per day). When the reported pain intensity is 7 or more out of 10, these participants will additionally undergo masticatory or cervical trigger point injections.

OTHER

Orofacial Bone Pain

Participants identified with orofacial bone pain disorder who report a pain intensity of less than 7 out of a possible 10 on the Numeric Verbal Rating Scale (NVRS) will receive non-opioid analgesics, including acetaminophen and non-steroidal anti-inflammatory medications. In cases where the pain intensity is 7 or more, participants will be offered targeted nerve blocks. These blocks will be performed along the sensory nerves supplying the affected region to provide localized pain relief.

OTHER

Neuralgia Pain

Participants classified with neuralgia will be treated with pregabalin (up to 600 mg per day) or carbamazepine (up to 1200 mg per day). Nerve blocks will be considered for those experiencing pain of 7 or more out of 10. In summary, participants with persistent pain disorder, burning disorder, or neuralgia phenotypes who present with pain intensity scores of 7 or higher will be given nerve blocks around the sensory nerves corresponding to the region of pain.

OTHER

Burning Pain

Participants with burning pain will receive pregabalin (up to 600 mg per day), carbamazepine (up to 1200 mg per day), or clonazepam (up to 2 mg per day), and if their pain intensity meets or exceeds 7 out of 10, nerve blocks will similarly be provided to target the sensory pathways involved.

OTHER

Persistent Pain

Those diagnosed with persistent pain disorder will be treated with either amitriptyline (up to 25 mg per day) or pregabalin (up to 600 mg per day). Participants in this group who report pain intensity of 7 or more will also be offered nerve blocks administered at sites corresponding to the involved sensory distribution.

Locations (1)

Shaukat Khanum Memorial Cancer Hospital & Research Centre

Lahore, Punjab Province, Pakistan